Clinical Trial Update: A Blinded Study To Examine The Ability Of PF-610,355 To Open The Airways In Asthmatic Patients. [Phase 2]

View source ↗

Summary

A blinded Phase 2 trial evaluated PF-610,355 for its ability to open airways in asthmatic patients. The study has completed, but no results are provided in the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• PF-610,355 (PF-610,355)

Snippet

Sponsor: Pfizer | Conditions: Asthma | Phase 2 | Status: COMPLETED